yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q37766378-A765E8FF-3EEE-4524-9F3E-74B1B9AC6EFA
Q37766378-A765E8FF-3EEE-4524-9F3E-74B1B9AC6EFA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37766378-A765E8FF-3EEE-4524-9F3E-74B1B9AC6EFA
Bortezomib: friend or foe of hemolytic anemia?
P2860
Q37766378-A765E8FF-3EEE-4524-9F3E-74B1B9AC6EFA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37766378-A765E8FF-3EEE-4524-9F3E-74B1B9AC6EFA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
81d147b7498efbb9109d9cbd78302a507cc0d639
P2860
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.